A Phase 4 interventional study of Physical Therapy and Standard of Care Analgesic Therapy in Post Operative Pain, sponsored by University of Miami. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Miami · Phase 4, Interventional, and Treatment
To evaluate the effectiveness of a protocolized physical therapy program in reducing postoperative chest and abdominal wall pain after minimally invasive thoracic surgery. To characterize neuropathic and nociceptive components of post-thoracotomy pain using the Perioperative Neuropathic Pain Assessment Form
5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.
This study's planned enrollment of 150 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →University of Miami is the lead sponsor of 842 studies on the registry; 166 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive standard postoperative analgesic therapy per routine clinical care throughout the study period. In addition, participants will complete protocolized physical therapy consisting of 1 session per week for 4 weeks, beginning at postoperative week 4. Total participation in this arm is approximately 6 months
Behavioral: Physical Therapy · Drug: Standard of Care Analgesic Therapy
Participants will receive standard postoperative analgesic therapy per routine clinical care throughout the study period. Total participation in this arm is approximately 6 months.
Drug: Standard of Care Analgesic Therapy
Protocolized physical therapy administered once weekly for 4 weeks beginning at postoperative week 4. Therapy includes chest wall strengthening, shoulder girdle mobilization, postural training, abdominal strengthening, inspiratory muscle training, and pain management modalities (cryotherapy, moist heat, ultrasound).
Postoperative analgesic therapy administered as part of routine clinical standard of care and determined by the treating physician. Medications may include acetaminophen (Tylenol), celecoxib (Celebrex), ibuprofen (Advil), ketorolac (Toradol), gabapentin (Neurontin), and oxycodone (OxyContin). Dosing, frequency, and duration will be individualized based on patient need and determined by the treating clinician.
Change in Postoperative Pain Intensity
Pain intensity will be measured using the Numeric Rating Scale (NRS), a patient-reported scale ranging from 0 (no pain) to 10 (worst possible pain). Time Frame: Baseline (2 weeks postoperatively), 8 weeks, and 6 months postoperatively
Time frame: Baseline (2 weeks postoperatively), 8 weeks, and 6 months postoperatively
Change in Neuropathic Pain Score
Neuropathic pain will be measured using the DN4 (Douleur Neuropathique en 4 Questions) questionnaire, with total scores ranging from 0 to 10. A score of ≥4 indicates the presence of neuropathic pain.
Time frame: Baseline (2 weeks postoperatively), 8 weeks, and 6 months postoperatively
Cumulative Opioid Exposure
Cumulative opioid exposure, calculated as the total morphine milligram equivalents (MME) of opioid medications used during the assessment periods
Time frame: 8 weeks, and 6 months postoperatively
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.
Of 531 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 12 months is below that.
Counting every sponsor, half of 541 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.